
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Important considerations regarding the production of high-quality empty hard capsules, critical excipients of finished pharmaceutical products.






